• Classic Hallucinogens for Addiction, Mood, and Anxiety Disorders

• Cannabidiol for Alcohol Use Disorder

• MDMA for Trauma- and Stressor-Related Disorders


• Cannabidiol for chronic non-cancer pain

• More research in development…


• Mechanism of Psychedelic-Induced Change in Animal Models of Psychiatric Disorders

We are currently performing clinical research with the following psychedelic drugs:
  • The classic hallucinogen psilocybin for treatment of alcohol use disorder
    PI: Michael Bogenschutz, MD

    [Funding for this research is provided by the Heffter Research Institute, B.More, and individual donations from Carey and Claudia Turnbull, Dr. Efrem Nulman, Rodrigo Niño, and Alan Fournier]

  • The classic hallucinogen psilocybin for treatment of major depressive disorder
    NYU Langone Site PI: Stephen Ross, MD

    [Funding for this research is provided by the Usona Institute.

  • The synthetic psychedelic MDMA for treatment of posttraumatic stress disorder
    NYU Langone Site PI: Michael Bogenschutz, MD

    [Funding for this research is provided by the Multidisciplinary Association for Psychedelic Studies (MAPS)]

We are also performing preclinical research with the following non-psychedelic drugs:
  • The classic hallucinogen LSD for investigation of neurocircuity alterations related to its effects on alcohol preference
    PI: Sarah Mennenga, PhD
    Co-I/Project Mentor: Tanya Sippy, MD/PhD

    [Funding for this research is provided by the NYU Langone Psychedelic Medicine Research Training Program, and MindMed, Inc.]

  • The non-hallucinogenic LSD derivative, BOL-148/2-bromo-LSD, for investigations of its effects on alcohol preference and related neurocircuitry
    PI: Sarah Mennenga, PhD
    Co-I/Project Mentor: Tanya Sippy, MD/PhD

    [Funding for this research is provided by CH TAC, the NYU Langone Psychedelic Medicine Research Training Program, and MindMed, Inc.]

    If you or your organization are interested in donating funding to support our research, please contact Marci Brenholz ( at NYU Langone’s Office of Development, with a cc to

Select Publications

Psilocybin-Assisted Treatment of Alcohol Use Disorder and Addiction

Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012 Jun;35(2):357-74. doi: 10.1016/j.psc.2012.04.002. PMID: 22640760.

Bogenschutz MP. Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Curr Drug Abuse Rev. 2013 Mar;6(1):17-29. doi: 10.2174/15733998113099990002. PMID: 23627783.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13. PMID: 25586396.

Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250-8. doi: 10.1016/j.pnpbp.2015.03.002. Epub 2015 Mar 14. PMID: 25784600.

Bogenschutz MP. It’s time to take psilocybin seriously as a possible treatment for substance use disorders. Am J Drug Alcohol Abuse. 2017 Jan;43(1):4-6. doi: 10.1080/00952990.2016.1200060. Epub 2016 Aug 24. PMID: 27558746.

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol. 2018 Feb 20;9:100. doi: 10.3389/fphar.2018.00100. PMID: 29515439; PMCID: PMC5826237.

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Front Pharmacol. 2018 Feb 21;9:132. doi: 10.3389/fphar.2018.00132. PMID: 29515449; PMCID: PMC5826346.

Psilocybin-Assisted Treatment of Cancer-Related Anxiety and Depression

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512. PMID: 27909164; PMCID: PMC5367551.

Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. 2018 Apr 3;9:256. doi: 10.3389/fphar.2018.00256. PMID: 29666578; PMCID: PMC5891594.

Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018 Aug;30(4):317-330. doi: 10.1080/09540261.2018.1482261. Epub 2018 Aug 13. PMID: 30102082.

Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020 Feb;34(2):155-166. doi: 10.1177/0269881119897615. Epub 2020 Jan 9. PMID: 31916890.

Therapeutic Applications of Psychedelics

Bogenschutz MP, Ross S. Therapeutic Applications of Classic Hallucinogens. Curr Top Behav Neurosci. 2018;36:361-391. doi: 10.1007/7854_2016_464. PMID: 28512684.

O’Donnell, KC, Mennenga, SE, & Bogenschutz, MP (2019). Psilocybin for depression: Considerations for clinical trial design, Journal of Psychedelic Studies, 3(3), 269-279. Retrieved Oct 3, 2020, from